Cancer and Neuroscience Led 2023 VC, M&A Investment in Biopharma

2023 was, by all accounts, a down year for investment in biopharma, and it ended on a low note with declines in licensing deals, venture investments, IPOs and M&A transactions in Q4, according to J.P. Morgan’s 2023 Annual Biopharma Licensing and Venture Report. But the year did bring significant investment for the oncology and neurosciences spaces—a trend experts expect to continue into 2024 and beyond.